ERBB2 and breast cancer: Improved cytotoxicity was also reached in a former PIT approach with an anti-EGFR panitumumab-IR700 conjugate in combination with an anti-HER-2 trastuzumab-IR700 conjugate compared to the corresponding monotherapies in BC cells [46].